Shanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System

Bulletin Express

10/31

Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.

According to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.

The company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1137849417"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1137849417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1137849417?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 00:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1137849417","market":"hk","top_or_hot":-1,"title":"Shanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System","media":"Bulletin Express","content":"<p>Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.</p>\n<p>According to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.</p>\n<p>The company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShanghai Bio-heart (2185) Announces UK MHRA Registration of Iberis® RDN System\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-10-31 00:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.</p>\n<p>According to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.</p>\n<p>The company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02185","symbol_name":"百心安-B","start_time":0,"source_url":"","article_id":"1137849417","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1137849417","pubTimestamp":1761843458,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02185":"百心安-B"},"translate_title":"上海生物心脏(2185)宣布Iberis获得英国MHRA注册®RDN系统","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02185":1},"content_text":"Shanghai Bio-heart Biological Technology Co., Ltd. (2185) announced that a subsidiary of the company, Shanghai AngioCare Medical Technology Co., Ltd., in collaboration with Biosensors International Group, Ltd., has successfully registered the Iberis® Multi-Electrode Renal Artery Radiofrequency Ablation Catheter System (Iberis® RDN system) with the Medicines & Healthcare products Regulatory Agency (MHRA) in the United Kingdom.\nAccording to the announcement, Iberis® RDN system is approved for both transradial and transfemoral approaches, and it previously received CE marking in Europe in 2016. The registration is part of a broader strategic partnership between AngioCare and Biosensors that encompasses commercialization in multiple regions, including the European Union, the Asia–Pacific region, and Latin America.\nThe company notes that there is no guarantee Iberis® RDN system will be successfully developed and marketed, and shareholders and potential investors are advised to exercise due care when dealing in its shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}